Adicet Bio, Inc. (LON:0HX7)
London
· Delayed Price · Currency is GBP · Price in USD 0.991
+0.002 (0.19%)
At close: Feb 21, 2025
Adicet Bio Employees
Adicet Bio had 143 employees as of December 31, 2023. The number of employees increased by 11 or 8.33% compared to the previous year.
Employees
143
Change (1Y)
11
Growth (1Y)
8.33%
Revenue / Employee
n/a
Profits / Employee
-615.06K GBP
Market Cap
63.45M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 143 | 11 | 8.33% |
| Dec 31, 2022 | 132 | 46 | 53.49% |
| Dec 31, 2021 | 86 | 4 | 4.88% |
| Dec 31, 2020 | 82 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 89,900 |
| GSK plc | 70,212 |
| Haleon | 25,408 |
| Smith & Nephew | 18,452 |
| Hikma Pharmaceuticals | 9,100 |
| ConvaTec Group | 10,136 |
| HUTCHMED (China) | 1,988 |
| Genus | 3,500 |
Adicet Bio News
- 18 days ago - Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement - Business Wire
- 22 days ago - Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 25 days ago - Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference - Business Wire
- 6 weeks ago - Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones - Business Wire
- 7 weeks ago - Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Business Wire
- 2 months ago - Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer - Business Wire
- 3 months ago - Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Business Wire